Home › Funds › Paradigm Biocapital Advisors LP › VRDN

Paradigm Biocapital Advisors LP position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Paradigm Biocapital Advisors LP reported holding 12,412,886 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$227.1M, representing 4.52% of its reported portfolio and ranking #6 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)12.41M sh
Reported value held$227.08M
Portfolio Weight4.52%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's VRDN position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in VRDN in Q3 2023 at 3,681,747 shares (US$56.5M). The position peaked in Q3 2026 at 12,412,886 shares, worth US$227.1M. Across 13 filings, Paradigm Biocapital Advisors LP increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 12,412,886 shares valued at US$227.1M — an increase of 5,689,098 shares quarter over quarter.. Notable position changes include a 118% increase in Q1 2026 (shares fell 6% over the following quarter), a 114% increase in Q2 2026 (shares rose 12% over the following quarter), a 85% increase in Q3 2026 (shares rose 50% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.68M $56.48M New
Q4 2023 4.79M $104.42M Add
Q1 2024 5.03M $88.10M Add
Q2 2024 2.90M $37.68M Reduce
Q3 2024 2.90M $65.88M Hold
Q4 2024 1.82M $34.89M Reduce
Q1 2025 2.10M $28.24M Add
Q2 2025 2.74M $38.33M Add
Q3 2025 2.61M $56.31M Reduce
Q4 2025 1.44M $44.91M Reduce
Q1 2026 3.15M $61.59M Add
Q2 2026 6.72M $123.52M Add
Q3 2026 12.41M $227.08M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M), RTW INVESTMENTS, LP (US$102.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held VRDN?

Paradigm Biocapital Advisors LP has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Paradigm Biocapital Advisors LP's current position in VRDN?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 12.41M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $227.08M, representing 4.52% of its reported portfolio and ranking #6.

Has Paradigm Biocapital Advisors LP been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in VRDN. The position peaked in Q3 2026 at 12.41M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Kynam Capital Management, LP, Bellevue Group AG, RTW INVESTMENTS, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.